An oncology CRO
As your full-service CRO partner, we bring a deep understanding across multiple disciplines to every oncology trial.
Aixial Group, a full-service CRO with an oncology focus since 1999
We specialise in serving the biopharma and biotech sectors, delivering a strategic, proactive partner in oncology clinical research. Our tailored solutions are built around the unique needs of each client, ensuring a personalised and collaborative approach in every engagement.
Our work in oncology trial designs
We excel in delivering trials evaluating the latest advances in investigational therapies. Our team is well-versed in a plethora of trial designs, including dose escalation, both biomarker-based and not, blind/double-blind, cross-over trials and others. Our experience enables our ability to help sponsors develop or deliver a personalised approach to medicine and an increased efficiency in investigational product development.
Our people, company culture, and can-do attitude, combined with our unique expertise in oncology and advanced technology, set us apart from the competition. We are a strategic partner adding value to the clinical development of our clients’ emerging therapies. We take pride in our commitment to delivering high-quality service.
Delivery Excellence in Oncology-Focused CRO Services
- Deep expertise in complex and innovative trial designs, incl. accelerated dose escalation modalities, adaptive, basket and umbrella studies.
- A specialised team with 100% oncology focus
- Dedicated teams for both early-phase and late-phase trials
- Proven ability to anticipate risks and implement mitigation strategies
- Technology-enabled operations
- A proactive, solution-driven partnership model
- Transparent, collaborative communication between our teams
Helping you succeed in your project
Examples of our intricate trial design experience
Interaction designs
Defined as enrolment of marker + and – patients with randomised to targeted vs. non-targeted therapy
Enrichment designs
Defined as enrolment of marker + patients only, with or without randomisation
Adaptive enrichment designs
Defined as adaptable enrolment during the trial from the full population to patients who seem to benefit from the product under study
Marker strategy designs
Defined as patients randomised to a treatment strategy: based on biomarker status vs. not based on biomarker status (e.g. physician’s choice)
Master protocols
Basket trials, umbrella trials, platform trials, etc
How can we support your next project?
Whether you’re looking for a protocol review or a proposal,
simply reach out to us by filling our request for proposal.
Insights
Other ways we support you
Helping you succeed in your project